Asahi Intecc said early this month that its board of directors agreed to acquire RetroVascular in a deal worth approximately $25.9 million.
Menlo Park, Calif.-based RetroVascular is developing cardiological tools for percutaneous transluminal coronary angioplasty procedures, specifically to treat chronic total occlusions.
Asahi said that it has maintained a collaborative relationship with RetroVascular to develop the PTCA treatment, which incorporates the use of plasma energy technology with the intention of improving PTCA treatment results.
Asahi Intecc said it will look for ways to incorporate the plasma energy technologies into its own devices, with hopes that it will be able to expand into fields outside cardiovascular use.
The company added that it hopes to use RetroVascular’s location in Silicon Valley “as a base for gathering and surveying most-advanced information,” according to a press release.
In April, Asahi Intecc revealed plans to begin direct sales of its coronary percutaneous transluminal coronary angioplasty guidewires in the US, which were previously only distributed by Abbott‘s (NYSE:ABT) vascular division.
